AbbVie stock gains ahead of earnings; ABBV investors brace for guidance and a $1.3 billion expense
AbbVie shares climbed $2.69, or 1.2%, on Monday, settling at $225.70 after hitting a session high of $229.80.
Merck stock rises ahead of earnings: MRK traders eye guidance and the Keytruda cliff
Merck & Co shares climbed roughly 2.2% on Monday, pushing the price up to $112.67 by midday. During the session, the stock fluctuated between $109.80 and $112.74.
Johnson & Johnson stock rises as new Erleada survival data lands
Johnson & Johnson shares rose on Monday after the company released fresh data on its prostate cancer drug Erleada, adding to a steady bid for large healthcare names in a firm U.S. market.
Eli Lilly stock price climbs as obesity-drug forecasts get a reality check before earnings
Shares of Eli Lilly and Company climbed roughly 1.5% on Monday, closing near $1,052.70, after fluctuating between $1,035.28 and $1,056.51 during the session.
GSK share price ticks up as cost-cutting talk swirls ahead of Feb. 4 results
Shares of GSK edged higher by 0.3% to 1,882.5 pence as of 0826 GMT, moving within a range of 1,875 to 1,890 pence earlier. Over the last 52 weeks, the stock has fluctuated between 1,242.5 and 1,909.5 pence.
Novo Nordisk stock heads into earnings week as Wegovy pill scripts top 26,000
Novo Nordisk A/S Class B shares ended Friday at 369.6 Danish crowns, slipping 0.8 crown. Investors brace for a results-packed week, keen on fresh demand figures for the company’s new weight-loss drug.
AstraZeneca stock price: NYSE switch, China bets and earnings put AZN in play this week
AstraZeneca announced its ordinary shares are set to begin trading on the New York Stock Exchange this Monday, following the withdrawal of its American depositary shares — the vehicle for U.S. trading — from Nasdaq. The company confirmed the AZN ticker will stay the same, with shares continuing to trade on the London Stock Exchange and Nasdaq Stockholm.
Novartis AG stock heads into earnings week after Friday close near 115 francs
Novartis shares closed Friday on the SIX Swiss Exchange at 114.62 Swiss francs, gaining 0.3% for the session. With markets closed over the weekend, attention shifts to the company’s upcoming update.
Healthcare stocks hold up as defensive bid lingers; Pfizer, Merck earnings set the tone
The Health Care Select Sector SPDR Fund, a popular collection of major U.S. healthcare stocks, ended Friday up roughly 0.6%, closing at $154.74. Nasdaq data indicated the fund carried a defensive bid into the weekend.
Roche stock price ends week higher — dividend vote and 2026 outlook set the tone for Monday
Roche shares closed Friday 1.1% higher at CHF 350.70, building on a two-day rally following volatile trading around its annual results.
Johnson & Johnson stock price: JNJ in focus after EU panel backs Akeega expansion
Johnson & Johnson shares closed Friday nearly flat, slipping just 0.01% to $227.25. The stock moves into Monday following a positive nod from European Medicines Agency advisers, who supported expanding the use of its prostate-cancer drug Akeega.)
Eli Lilly stock: LLY ends higher after $3.5 billion Pennsylvania plant plan as earnings near
Eli Lilly shares ended Friday up roughly 1.3%, closing at $1,037.15. The company unveiled a $3.5 billion initiative to boost U.S. manufacturing for its weight-loss business. Market data pegs the stock’s value at around $986 billion.
Amgen stock heads into earnings week after ending Kyowa Kirin eczema pact
Amgen shares slipped roughly 0.3% to $341.88 on Friday, barely moving ahead of a busy week packed with catalysts. The biotech is set to unwind its partnership with Japan’s Kyowa Kirin.
Novo Nordisk Class B stock price: Wegovy pill scripts hit 26,000 as earnings week approaches
Novo Nordisk’s Class B shares on the Copenhagen exchange slipped 0.23% to 369.55 Danish kroner Friday, marking roughly a 7.9% drop over the past five sessions. Investors now face a short weekend to process an expanding roster of catalysts.
Novartis stock price: NVS near $149 as Feb. 4 earnings approach — what to watch
Novartis AG’s U.S.-listed ADRs — representing the Swiss shares — dipped 0.1% on Friday, closing at $148.68 after fluctuating between $148.05 and $149.89. Roughly 1.15 million ADRs were traded.
AstraZeneca share price: $18.5 billion China obesity-drug deal puts AZN stock in focus for Monday
AstraZeneca PLC shares climbed on Friday after the drugmaker struck a deal to license obesity and weight management drug candidates from CSPC Pharmaceutical Group, in a pact valued at up to $18.5 billion. CSPC revealed AstraZeneca would pay $1.2 billion upfront, with an additional $17.3 billion contingent on meeting milestones. Tony Ren of Macquarie Capital described the move as a “buy the rumour, sell the news” play, after CSPC’s shares dropped nearly 12% in Hong Kong.
Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised
Healthcare shares ended Friday stronger than the wider market following Eli Lilly’s announcement of a $3.5 billion manufacturing facility in Pennsylvania dedicated to injectable weight-loss drugs. CEO David Ricks described the new plant as “really state of the art manufacturing to last many decades to come” during a press briefing.
AbbVie stock (ABBV) firms up into earnings week as markets turn cautious
AbbVie Inc. shares climbed 1.17% to close at $223.01 on Friday, outperforming the broader market. Investors are gearing up for the drugmaker’s upcoming earnings report next week.
Johnson & Johnson stock: Talc-court twist and EU drug nod set up next week
Johnson & Johnson shares edged down 3 cents to $227.25 on Friday after a U.S. judge dismissed a lawsuit accusing the company of fraud related to its talc bankruptcy approach. The plaintiffs claimed J&J employed a “Texas two-step,” moving talc liabilities into a subsidiary that filed for bankruptcy to stall cancer lawsuits. Judge Michael Shipp ruled they hadn’t proven any real harm caused by the delay. J&J’s litigation head Erik Haas slammed the claims as “wholly meritless,” while the plaintiffs’ attorney said they’re considering an appeal.
Eli Lilly stock price (LLY): $3.5B plant, EU Mounjaro call and earnings ahead — what to watch
Shares of Eli Lilly finished Friday up about 1.3%, closing at $1,037.15. The boost came after the company unveiled a $3.5 billion plan for a new manufacturing facility in Pennsylvania. This plant will produce injectable weight-loss drugs, including retatrutide—a next-gen medication Lilly says has outperformed Zepbound. “All these sites, including this one, will be really state of the art manufacturing to last many decades to come,” CEO David Ricks said in Allentown. Drugmakers like Pfizer and Merck & Co are also expanding U.S. capacity amid Donald Trump’s threat of import tariffs. Meanwhile, Lilly is racing Novo Nordisk for U.S. approval of an oral weight-loss pill, which it plans to price at $150 a month and launch in several countries.